Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of responses to immune checkpoint blockade in advanced melanoma.
Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L. Jacquelot N, et al. Among authors: aubin f. Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2. Nat Commun. 2017. PMID: 28928380 Free PMC article.
Gluten intolerance and skin diseases.
Humbert P, Pelletier F, Dreno B, Puzenat E, Aubin F. Humbert P, et al. Among authors: aubin f. Eur J Dermatol. 2006 Jan-Feb;16(1):4-11. Eur J Dermatol. 2006. PMID: 16436335 Review.
Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis.
Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Semeraro M, Jégou S, Flores C, Chen L, Kwon BS, Borg C, Weide B, Aubin F, Dalle S, Kohrt H, Ayyoub M, Kroemer G, Marabelle A, Cavalcanti A, Eggermont A, Zitvogel L. Jacquelot N, et al. Among authors: aubin f. J Invest Dermatol. 2016 May;136(5):994-1001. doi: 10.1016/j.jid.2015.12.042. Epub 2016 Jan 29. J Invest Dermatol. 2016. PMID: 26829031 Free PMC article.
[Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer].
Jacquin-Porretaz C, Nardin C, Puzenat E, Roche-Kubler B, Aubin F; Comité de suivi des effets secondaires des immunothérapies anti-cancéreuses(CSESIAC). Jacquin-Porretaz C, et al. Among authors: aubin f. Presse Med. 2017 Sep;46(9):808-817. doi: 10.1016/j.lpm.2017.05.032. Epub 2017 Jul 3. Presse Med. 2017. PMID: 28683958 Review. French.
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.
Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Brunet-Possenti F, Arnault JP, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Rotolo F, Ballon A, Michiels S, Lebbe C, Borget I. Kandel M, et al. Among authors: aubin f. Eur J Cancer. 2018 Dec;105:33-40. doi: 10.1016/j.ejca.2018.09.026. Epub 2018 Oct 29. Eur J Cancer. 2018. PMID: 30384014
Quality-of-life assessment in French patients with metastatic melanoma in real life.
Kandel M, Dalle S, Bardet A, Allayous C, Mortier L, Dutriaux C, Guillot B, Leccia MT, Dalac S, Legoupil D, Saiag P, Montaudie H, Arnault JP, Brunet-Possenti F, Grob JJ, DeQuatrebarbes J, Beylot-Barry M, Lesimple T, Aubin F, Maubec E, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I. Kandel M, et al. Among authors: aubin f. Cancer. 2020 Feb 1;126(3):611-618. doi: 10.1002/cncr.32554. Epub 2019 Oct 22. Cancer. 2020. PMID: 31639198 Free article.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C; EORTC Melanoma Group. Eggermont AMM, et al. Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857412 Clinical Trial.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM; EORTC Melanoma Group. Bottomley A, et al. Lancet Oncol. 2021 May;22(5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857414 Clinical Trial.
568 results